$-0.04
(Market cap
$2 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.8 %
-
ROCE
-- %
-
Industry P/E
27.89
-
EV/EBITDA
0
-
Debt to Equity
0.3
-
Book Value
$--
-
EPS
$-3.1
-
Face value
--
-
Shares outstanding
3,200,824
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Valion Bio Inc (VBIO)
| -61.3 | -49.5 | -36.9 | -85.3 | -84.8 | -- | -- |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Valion Bio Inc (VBIO)
|
0.6 | 2.4 | 1.5 | -7.3 | 0.0 | -55.3 | -- | 0.2 |
| 45.1 | 3,676.4 | 529.0 | 149.2 | 4.5 | 30.2 | 25.9 | 6.5 | |
| 18.5 | 3,836.3 | 1,156.7 | 126.1 | 24.3 | 3.5 | 29.9 | 1.0 | |
| 10.1 | 81.2 | 0.0 | 0.5 | -- | 1.9 | -- | 0.0 |
Shareholding Pattern
View DetailsAbout Valion Bio Inc (VBIO)
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat... Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas. Read more
-
Exec. Chairman
Hon. Edward Farrell Feighan
-
CEO & Director
Mr. Michael Kevin Handley
-
Headquarters
San Antonio, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Valion Bio Inc (VBIO)
What is the current share price of Valion Bio Inc (VBIO) Today?
The share price of Valion Bio Inc (VBIO) is $0.56 (NASDAQ) as of 12-Jun-2026 13:34 EDT. Valion Bio Inc (VBIO) has given a return of -84.81% in the last 3 years.
What is the current PB & PE ratio of Valion Bio Inc (VBIO)?
Since, TTM earnings of Valion Bio Inc (VBIO) is negative, P/E ratio is not available.
The P/B ratio of Valion Bio Inc (VBIO) is 0.21 times as on 05-Jun-2026, a 79 discount to its peers’ median range of 0.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.41
|
0.22
|
|
2024
|
-0.58
|
1.29
|
|
2023
|
-188.23
|
433.45
|
|
2022
|
-5,464.89
|
15,199.33
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Valion Bio Inc (VBIO)?
The 52-week high and low of Valion Bio Inc (VBIO) are Rs 5.60 and Rs 0.52 as of 13-Jun-2026.
What is the market cap of Valion Bio Inc (VBIO)?
Valion Bio Inc (VBIO) has a market capitalisation of $ 2 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Valion Bio Inc (VBIO)?
Before investing in Valion Bio Inc (VBIO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.